Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy and Safety of an AI-Driven Treatment Strategy Versus Pola-R-CHP in Patients With Previously Untreated Large B-Cell Lymphoma

NCT07594899 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07594899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07594899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy and Safety of an AI-Driven Treatment Strategy Versus Pola-R-CHP in Patients With Previously Untreated Large B-Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 6, 2026
Completion date
December 31, 2029
Enrollment
178 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma (lbcl)